November 9th, 2026FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene TherapyPostmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.Read more